. Growth inhibition from expressing the site-mutants of Pdr transcription factors and determination of suitable galactose concentration. (A) Growth curves under induction by 20 g/l galactose. Control, BYL13 with pESC-Ura, Pdr1 mt1 (Pdr1 F815S), Pdr1 mt2 (Pdr1 R821S), Pdr1 mt1+2 (Pdr1 F815S R821S), Pdr3 mt (Pdr3 Y276H). (B) Growth inhibition from the coexpressed Pdr1 mt1+2 and Pdr3 mt under induction by galactose (Gal) at concentrations of 0.5 g/l, 5 g/l, and 20 g/l. Growth of BYL13 with pESC-Ura at each time point was set to 100%. Error bars, SD from three biological replicates.
. Determination of alkane exposure concentrations. BYL13 with pESC-Ura was incubated in induction media added with 0.5 g/l galactose, without alkane (A) and with different amounts of C8 (B), C9 (C), C10 (D), and C11 (E) alkanes. Error bars, SD from three biological replicates. Figure S3 . Growth of BYL13 expressing Pdr transcription factors in the presence of alkanes. Under induction by 0.5 g/l galactose, BYL13 expressing Pdr transcription factors were exposed to 1% C10 and 5% C11, respectively. Wild type (WT) and site-mutants (MT) of Pdr1p and Pdr3p are indicated. Control, BYL13 with pESC-Ura. Error bars, SD from three biological replicates. Under induction by 0.5 g/l galactose, BY4741 with pESC-Ura, Pdr1 mt1 +Pdr3 mt , and Pdr3 wt were exposed to 1% C10 (diamond) and 5% C11 (square), respectively. Cell densities (OD 600 ) were measured and compared every 12 h. Error bars, SD from three biological replicates.
